A rationale for gene targeting in glaucoma therapy

M. Wax, R. Patil

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

One of the mainstays of glaucoma treatment is the use of drugs that decrease the secretion of aqueous humor fluid from the ciliary epithelium. Unfortunately, many currently available drugs that decrease aqueous humor production such as β-adrenergic antagonists, may cause serious systemic side effects such as cardiac arrythmias and arrest, pulmonary dysfunction, and CNS side effects such as decreased libido and depression. Efforts to develop effective aqueous suppressants that offer decreased morbidity and mortality in comparison to those currently available will likely rely on the ability to alter the function of specific cellular events which underlie aqueous humor production by the ciliary epithelium. However, the secretory process which results in aqueous humor production is incompletely understood and the identification of precise cellular mechanisms which underlie this process remain to be established. We will present a rationale for genetic approaches to regulate gene expression so that aqueous humor production may be specifically targeted in glaucoma patients. Techniques of gene transfer including homologous exchange recombination, and expression of antisense genes, will be discussed.

Original languageEnglish (US)
Pages (from-to)403-410
Number of pages8
JournalJournal of Ocular Pharmacology
Volume10
Issue number1
StatePublished - 1994

Fingerprint

Gene Targeting
Aqueous Humor
Glaucoma
Epithelium
Therapeutics
Gene Expression
Libido
Gene Transfer Techniques
Adrenergic Antagonists
Aptitude
Secretory Pathway
Homologous Recombination
Heart Arrest
Pharmaceutical Preparations
Cardiac Arrhythmias
Depression
Morbidity
Lung
Mortality

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A rationale for gene targeting in glaucoma therapy. / Wax, M.; Patil, R.

In: Journal of Ocular Pharmacology, Vol. 10, No. 1, 1994, p. 403-410.

Research output: Contribution to journalArticle

Wax, M & Patil, R 1994, 'A rationale for gene targeting in glaucoma therapy', Journal of Ocular Pharmacology, vol. 10, no. 1, pp. 403-410.
Wax, M. ; Patil, R. / A rationale for gene targeting in glaucoma therapy. In: Journal of Ocular Pharmacology. 1994 ; Vol. 10, No. 1. pp. 403-410.
@article{71d104473b084e009a20d2f09be950df,
title = "A rationale for gene targeting in glaucoma therapy",
abstract = "One of the mainstays of glaucoma treatment is the use of drugs that decrease the secretion of aqueous humor fluid from the ciliary epithelium. Unfortunately, many currently available drugs that decrease aqueous humor production such as β-adrenergic antagonists, may cause serious systemic side effects such as cardiac arrythmias and arrest, pulmonary dysfunction, and CNS side effects such as decreased libido and depression. Efforts to develop effective aqueous suppressants that offer decreased morbidity and mortality in comparison to those currently available will likely rely on the ability to alter the function of specific cellular events which underlie aqueous humor production by the ciliary epithelium. However, the secretory process which results in aqueous humor production is incompletely understood and the identification of precise cellular mechanisms which underlie this process remain to be established. We will present a rationale for genetic approaches to regulate gene expression so that aqueous humor production may be specifically targeted in glaucoma patients. Techniques of gene transfer including homologous exchange recombination, and expression of antisense genes, will be discussed.",
author = "M. Wax and R. Patil",
year = "1994",
language = "English (US)",
volume = "10",
pages = "403--410",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - A rationale for gene targeting in glaucoma therapy

AU - Wax, M.

AU - Patil, R.

PY - 1994

Y1 - 1994

N2 - One of the mainstays of glaucoma treatment is the use of drugs that decrease the secretion of aqueous humor fluid from the ciliary epithelium. Unfortunately, many currently available drugs that decrease aqueous humor production such as β-adrenergic antagonists, may cause serious systemic side effects such as cardiac arrythmias and arrest, pulmonary dysfunction, and CNS side effects such as decreased libido and depression. Efforts to develop effective aqueous suppressants that offer decreased morbidity and mortality in comparison to those currently available will likely rely on the ability to alter the function of specific cellular events which underlie aqueous humor production by the ciliary epithelium. However, the secretory process which results in aqueous humor production is incompletely understood and the identification of precise cellular mechanisms which underlie this process remain to be established. We will present a rationale for genetic approaches to regulate gene expression so that aqueous humor production may be specifically targeted in glaucoma patients. Techniques of gene transfer including homologous exchange recombination, and expression of antisense genes, will be discussed.

AB - One of the mainstays of glaucoma treatment is the use of drugs that decrease the secretion of aqueous humor fluid from the ciliary epithelium. Unfortunately, many currently available drugs that decrease aqueous humor production such as β-adrenergic antagonists, may cause serious systemic side effects such as cardiac arrythmias and arrest, pulmonary dysfunction, and CNS side effects such as decreased libido and depression. Efforts to develop effective aqueous suppressants that offer decreased morbidity and mortality in comparison to those currently available will likely rely on the ability to alter the function of specific cellular events which underlie aqueous humor production by the ciliary epithelium. However, the secretory process which results in aqueous humor production is incompletely understood and the identification of precise cellular mechanisms which underlie this process remain to be established. We will present a rationale for genetic approaches to regulate gene expression so that aqueous humor production may be specifically targeted in glaucoma patients. Techniques of gene transfer including homologous exchange recombination, and expression of antisense genes, will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=0028287080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028287080&partnerID=8YFLogxK

M3 - Article

C2 - 8207343

AN - SCOPUS:0028287080

VL - 10

SP - 403

EP - 410

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 1

ER -